Key points
- Revenue from ordinary activities decreased by 5.8% to $14,758,461
- Loss from ordinary activities after tax increased by 38.7% to $(20,721,356)
- Core testing revenue grew by 92% to approximately $8.6 million
- Gross margin remained stable at 47.6%
- Total operating expenditure decreased by 7% to $29.9 million
Full summary
Microba Life Sciences Ltd reported a 5.8% decrease in revenue to $14.76 million for the year ended 30 June 2026. The decrease was entirely due to the planned phase-out of discontinued legacy products. Continuing product revenue grew 53% to $12.7 million, while discontinued product revenue reduced 72% to $2.1 million. Core testing revenue grew 92% to approximately $8.6 million, representing 62% of Q4 FY26 revenue. The company exited FY26 at a rolling-quarter annualized run-rate above 25,000 tests. Gross margin remained stable at 47.6%, and total operating expenditure decreased by 7% to $29.9 million. The statutory loss after tax increased to $20.7 million from $14.9 million in FY25, primarily reflecting non-cash and non-recurring items. Excluding those items, the underlying loss improved by 11%.
Guidance
Underlying loss improved 11% to $18.8 million, on operating expenditure down 7%
Outlook
The company aims to achieve whole company cash flow break-even, on a run-rate basis, in calendar year 2027.